GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.

US-based rare disease drug developer Fulcrum Therapeutics raised $72m in its initial public offering on Wednesday, providing exits to pharmaceutical firms GlaxoSmithKline (GSK), Sanofi and WuXi AppTec. The company issued 4.5 million shares priced at $16 each to list on the Nasdaq Global Market. Shares suffered a drop to $12.86 on the first day of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.